Clinical Trial Update: EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the optimization of anemia management with epoetin alfa (EPREX) in predialysis patients with chronic kidney disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Eprex (epoetin alfa)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Chronic Renal Failure | Phase 4 | Status: COMPLETED